Industry Symposia
The Industry Symposia offer a unique platform for our valued sponsors to showcase cutting-edge research, present innovative solutions, and engage with the transplant community.
We invite all congress participants to explore the symposia below and take part in these high-value educational opportunities.
| Sunday 29 June | Monday 30 June | Tuesday 1 July |
|---|---|---|
| Biotest | 15:30 – 16:30 BST | Takeda | 08:00 – 09:00 BST | Aferetica | 08:00 – 09:00 BST |
| MSD | 15:30 – 16:30 BST | CareDx | 13:00 – 14:00 BST | Astellas | 08:00 – 09:00 BST |
| PeerVoice | 15:30 – 16:30 BST | Hansa Biopharma | 13:00 – 14:00 BST | Thermo Fisher Scientific | 08:00 – 09:00 BST |
| XVIVO | 13:00 – 14:00 BST | Eurofins | 13:00 – 14:00 BST | |
| Chiesi | 17:45 – 18:45 | OrganOx | 13:00 – 14:00 BST | |
| Therakos | 13:00 – 14:00 BST |
Cytomegalovirus (CMV) infection remains a major challenge in transplantation, often impacting long-term graft survival and patient outcomes. The Biotest industry symposium brings together leading experts to discuss current perspectives and strategies for preventing CMV in transplant recipients. Join us for an engaging session as we explore the unmet medical needs in CMV and examine the role of immunoglobulins in its prevention.
(This educational symposium has been organised and fully funded by MSD. MSD products will be mentioned at this symposium.)
Join us for a symposium featuring a panel of experts who will share the latest clinical advancements in managing cytomegalovirus (CMV) in kidney transplantation, including updated guidelines. The expert panel will cover recent clinical trial data, specific needs of frail populations, and practical approaches to optimize patient outcomes in CMV management.
Dr. Klemens Budde will present updates to post-transplant CMV management guidelines, addressing practical challenges such as leukopenia and neutropenia. Dr. Flavio Vincenti will review the latest clinical trial data regarding CMV prevention, while Dr. Nassim Kamar will focus on the benefits of adopting a personalized approach to CMV management for certain kidney transplant patients.
We invite you to deepen your understanding of the latest clinical advances in tailored CMV management strategies and their potential implications for kidney transplantation.
(Prescribing information will be available at the symposium) (GB-NON-11226 - April 2025) [JG1]
This symposium provides a comprehensive exploration of strategies to improve long-term graft survival in solid organ transplant recipients. The session begins with an engaging introduction that highlights the ongoing challenges of achieving optimal long-term outcomes with current immunosuppressive therapies, including their limited efficacy and safety over time. Faculty then present the rationale for developing risk prediction tools, such as iBOX, and discuss their potential as surrogate endpoints in clinical trials to drive therapeutic advancement. A panel discussion further explores the clinical utility and real-world application of these predictive tools in assessing long-term outcomes. The symposium culminates with a focus on costimulatory blockade, examining its mechanistic basis and the current evidence from agents like belatacept. The faculty also address ongoing research into alternative costimulatory pathways that could offer new therapeutic opportunities. The overall educational objective is to enhance transplant healthcare professionals’ understanding of innovative approaches to predicting and improving graft survival, with an emphasis on emerging trial endpoints and investigational immunomodulatory strategies. Learning objectives include recalling current survival rates, evaluating composite scoring systems, understanding surrogate endpoint development, and identifying promising costimulatory blockade approaches.
This activity is supported by an educational grant from Veloxis Pharmaceuticals, Inc.
Join Prof Colin Wilson and the faculty as they consider the challenges they currently face when managing post-transplant CMV infections in solid organ transplant recipients, including the practical management of the various factors that influence treatment decisions.
Just like there are many factors that influence physician decisions and patient outcomes, there are many stars in the galaxy. Our goal is to draw an analogy and highlight which factors, or which stars, making up the pattern of constellations, are the most important to consider when making these practical decisions.
Speakers will highlight patient cases and their clinical experience to understand how the trajectory of disease and current anti-CMV therapies influence clinical practice to advance patient outcomes. In this context, they will also discuss clinical trial and real-world data, including the Genome Canda Study exemplifying the importance of viral load kinetics on patient outcomes, and the updated guidelines on CMV management in solid organ transplant recipients.
Surveillance after allograft transplantation is critical for the detection and treatment of rejection and prevention of chronic allograft dysfunction. Sub-clinical and clinical rejection leads to elevated levels of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients. This symposium will discuss the latest data on dd-cfDNA, emphasizing its role in optimizing clinical decision-making and improving patient care. Key topics include the significance of baseline dd-cfDNA values, the high negative predictive value of dd-cfDNA, association with a variety of rejection types including MVI, and interpretation of numerous contexts of use for. The session will also explore the role of dd-cfDNA in improving biopsy yield. Attendees will gain practical insights into integrating dd-cfDNA testing into transplant monitoring workflows consistent with published guidelines.
Desensitisation with imlifidase to enable HLAi kidney transplant is a relatively recent development which can help make transplant a reality for selected patients. With a recognised speaker panel the Hansa symposium will be centred around the patient journey with presentations on new long term data as well as real world experience and learnings. An interactive panel discussion will be devoted to critical issues from patient and centre readiness to post transplant patient management.
The demand for donor organs continues to outpace supply. To bridge the gap, transplant teams seek an alternative to conventional preservation – one that can widen the donor pool and improve transplant outcomes.
Join us to explore how Hypothermic Oxygenated Perfusion (HOPE) is showing significant promise and how the body of supporting evidence is growing.
In this symposium, leading experts will discuss the simplicity, safety and cost-effectiveness of HOPE in liver transplantation, review the evidence on machine perfusion for liver and kidney, and present novel insights into renal resistance as viability tool.
Discover the power of HOPE—and how it is shaping the future of organ preservation.
Personalization of care has a multitude of facets influencing clinical decisions that may range from the inclusion of innovative biomarkers and tools to the choice of a specific drug formulation based on patient characteristics. This symposium will explore allocation algorithms, new data and technological approaches and how these may be integrated in a holistic patient management to ultimately improve patients’ satisfaction and quality of life after transplant.
At the symposium, the latest advancements in organ preservation and ex-situ perfusion treatments will be presented to discuss how to address the challenging needs in transplantation and optimise the current preservation and perfusion procedures.
Astellas Pharma Inc. invites you to a dynamic, expert-led symposium featuring top international thought leaders where together we will:
• Celebrate decades of progress in transplant medicine and explore transformative breakthroughs in kidney and liver transplantation
• Delve into best practices for optimising long-term patient care, focusing on immunosuppressant management, minimising adverse events, and balancing quality of life with rejection prevention
• Engage in discussions on the future of transplantation, including innovations like artificial intelligence and robotic surgery through interactive case studies
This symposium is your opportunity to connect with leading experts and contribute to the ongoing evolution of transplant medicine.
Diagnostic tools such as MMDx and dd-cfDNA can each play a significant role in early rejection detection and management of transplant rejection. The symposium will highlight how MMDx can provide detailed molecular insights from biopsy samples, allowing for the identification of specific rejection types and other forms of graft injury. Attendees can also discover how Donor-derived cell-free DNA (dd-cfDNA) can serve as a non-invasive biomarker for monitoring graft health and detecting graft injury and rejection in adult and pediatric patients post-transplant. Through the experience of our two presenters, attendees have the opportunity to gain a deeper understanding of how novel and established biomarkers can enhance the assessment of rejection and injury for improved patient outcomes.
Join three world-renowned doctors, Dr. John Friedewald of Northwestern University in the United States, Dr. Pedro Ventura of Hospital Clinic Barcelona, and Dr. Gregor Bond of the Medical University of Vienna, for an engaging discussion on changing the post-transplant testing landscape to optimize immunosuppression.
Dr. Friedewald will review how adding viral load analysis to dd-cfDNA has the potential to provide unprecedented insight into the status of the graft, offering more comprehensive information than ever before. Dr. Bond will discuss how Torque Teno Virus (TTV) is emerging as a biomarker for immune function, with its plasma load serving as an indicator of immune status and a potential predictor of rejection and infection in solid organ transplant recipients. Dr. Ventura will speak on Gene Expression Profiling and its use in multi-organ transplant patients, focusing on his SPK study using this technology.
This symposium will offer valuable insights for healthcare professionals seeking to enhance post-transplant care and enhance patient outcomes.
Liver NMP: Why? When? How?
Tuesday 1 July | 13:00–14:00 BST
Room S3
Chaired by Prof. Peter Friend, Professor of Transplantation at the University of Oxford, and co-founder of OrganOx, this symposium explores the various ways in which NMP is being applied in different healthcare environments around the world. It will address the science, economics, and implementation of NMP.
Dr. Vijay Subramanian, Associate Professor at the University of South Florida and Associate Liver Surgical Director at Tampa General Hospital Transplant Institute, Florida, has completed over 500 NMP liver transplants. Hear how the Tampa group has used NMP as the standard of care by changing the logistics of liver transplantation.
Dr. Carlo Ceresa, Liver Transplant Surgeon at the Royal Free Hospital, London, has been involved in the experimental and clinical development of NMP for more than 10 years. He will analyse the evolution of NMP to standard of care in a European environment with specific reference to the financial and logistical constraints.
Prof. Nathanael Raschzok, Hepatobiliary and Transplant Surgeon at Charité - Universitätsmedizin Berlin, has been awarded national funding to research machine perfusion as a means to reduce the shortage of donor organs in Germany. He will discuss the role of NMP, particularly its potential to add value in high-risk donors including DCD.
